<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="other" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Surgery and Oncology</journal-id><journal-title-group><journal-title xml:lang="en">Surgery and Oncology</journal-title><trans-title-group xml:lang="ru"><trans-title>Хирургия и онкология</trans-title></trans-title-group></journal-title-group><issn publication-format="electronic">2949-5857</issn><publisher><publisher-name xml:lang="en">Publishing House ABV Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">103</article-id><article-id pub-id-type="doi">10.17650/2220-3478-2013-0-3-50-55</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>ORIGINAL REPORTS</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ ИССЛЕДОВАНИЯ</subject></subj-group><subj-group subj-group-type="article-type"><subject></subject></subj-group></article-categories><title-group><article-title xml:lang="en">MODERN TECHNOLOGIES IN SQUAMOUS-CELL ANAL CANCER RADIOTHERAPY PLANNING AND TREATMENT</article-title><trans-title-group xml:lang="ru"><trans-title>СОВРЕМЕННАЯ ТЕХНОЛОГИЯ ПОДГОТОВКИ И ПРОВЕДЕНИЯ ЛУЧЕВОЙ ТЕРАПИИ БОЛЬНЫХ ПЛОСКОКЛЕТОЧНЫМ РАКОМ АНАЛЬНОГО КАНАЛА</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Tkachev</surname><given-names>S. I.</given-names></name><name xml:lang="ru"><surname>Ткачев</surname><given-names>С. И.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>oncovalery@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Glebovskaya</surname><given-names>V. V.</given-names></name><name xml:lang="ru"><surname>Глебовская</surname><given-names>В. В.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>oncovalery@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Yazhgunovich</surname><given-names>I. P.</given-names></name><name xml:lang="ru"><surname>Яжгунович</surname><given-names>И. П.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>oncovalery@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Vodyanik</surname><given-names>V. V.</given-names></name><name xml:lang="ru"><surname>Водяник</surname><given-names>В. В.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>oncovalery@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">N.N. Russian Blokhin Cancer Research Center, Russian Academy of Medical Sciences, Moscow</institution></aff><aff><institution xml:lang="ru">ФГБУ «РОНЦ им. Н.Н. Блохина» РАМН, Москва</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2013-09-27" publication-format="electronic"><day>27</day><month>09</month><year>2013</year></pub-date><volume>2</volume><issue>3</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>50</fpage><lpage>55</lpage><history><date date-type="received" iso-8601-date="2015-03-02"><day>02</day><month>03</month><year>2015</year></date><date date-type="accepted" iso-8601-date="2015-03-02"><day>02</day><month>03</month><year>2015</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2013, Tkachev S.I., Glebovskaya V.V., Yazhgunovich I.P., Vodyanik V.V.</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2013, Ткачев С.И., Глебовская В.В., Яжгунович И.П., Водяник В.В.</copyright-statement><copyright-year>2013</copyright-year><copyright-holder xml:lang="en">Tkachev S.I., Glebovskaya V.V., Yazhgunovich I.P., Vodyanik V.V.</copyright-holder><copyright-holder xml:lang="ru">Ткачев С.И., Глебовская В.В., Яжгунович И.П., Водяник В.В.</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://onco-surgery.info/jour/article/view/103">https://onco-surgery.info/jour/article/view/103</self-uri><abstract xml:lang="en"><p>Squamous-cell anal cancer is a rare disease that requires a comprehensive approach in treatment and skilled professionals. Modern diagnostics is important for rational choice of treatment tactics. Radiotherapy is the cornerstone of sphincter-sparing anal cancer treatment. Radiotherapy dose, volume and duration are the key factors affecting treatment efficacy and toxicity.3D-conformal radiotherapy is a priority treatment allowing exact reproduction of treatment conditions, controlled by OBI (on-board imager) and kV X-Ray and cone-beam CT analysis. Intensity-modulated radiation therapy (IMRT) is a next-generation treatment with improved technologies, allowing better protection of normal tissues.Our experience with 21 squamous-cell anal cancer patients treated with IMRT during Nov 2011 – March 2013 is presented in this article.</p></abstract><trans-abstract xml:lang="ru"><p/></trans-abstract><kwd-group xml:lang="en"><kwd>epithelial anal cancer</kwd><kwd>3D-conformal radiotherapy</kwd><kwd>dose-volume histograms</kwd><kwd>organs at risk</kwd><kwd>intensity-modulated radiation therapy</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>рак анального канала</kwd><kwd>конформная лучевая терапия</kwd><kwd>дозообъемные гистограммы</kwd><kwd>критические структуры</kwd><kwd>терапия с модуляцией интенсивности</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><citation-alternatives><mixed-citation xml:lang="en">1. Кныш В.И., Тимофеев Ю.М. Злокачественные опухоли анального канала. М., 1997. С. 12.</mixed-citation><mixed-citation xml:lang="ru">Кныш В.И., Тимофеев Ю.М. Злокачественные опухоли анального канала. М., 1997. С. 12.</mixed-citation></citation-alternatives></ref><ref id="B2"><label>2.</label><citation-alternatives><mixed-citation xml:lang="en">2. Ткачев С.И., Глебовская В.В., Тимофеев Ю.М. Применение комбинированного консервативного метода лечения больных плоскоклеточным раком анального канала. Мат. III Всероссийского национального конгресса лучевых диагностов и терапевтов «Радиология 2009». Москва, 26–29 мая 2009 г. С. 412.</mixed-citation><mixed-citation xml:lang="ru">Ткачев С.И., Глебовская В.В., Тимофеев Ю.М. Применение комбинированного консервативного метода лечения больных плоскоклеточным раком анального канала. Мат. III Всероссийского национального конгресса лучевых диагностов и терапевтов «Радиология 2009». Москва, 26–29 мая 2009 г. С. 412.</mixed-citation></citation-alternatives></ref><ref id="B3"><label>3.</label><citation-alternatives><mixed-citation xml:lang="en">3. Ткачев С.И., Барсуков Ю.А., Глебовская В.В. Патент РФ № 2427399 Способ лечения плоскоклеточного рака анального канала.</mixed-citation><mixed-citation xml:lang="ru">Ткачев С.И., Барсуков Ю.А., Глебовская В.В. Патент РФ № 2427399 Способ лечения плоскоклеточного рака анального канала.</mixed-citation></citation-alternatives></ref><ref id="B4"><label>4.</label><citation-alternatives><mixed-citation xml:lang="en">4. Аминев А.М. Руководство по проктологии. Т. 1. Куйбышев, 1965. С. 518.</mixed-citation><mixed-citation xml:lang="ru">Аминев А.М. Руководство по проктологии. Т. 1. Куйбышев, 1965. С. 518.</mixed-citation></citation-alternatives></ref><ref id="B5"><label>5.</label><citation-alternatives><mixed-citation xml:lang="en">5. Singh R., Nime F., Mittelman A. Malignant epithelian tumors of the anal canal. Cancer 1981;48(2):411–5.</mixed-citation><mixed-citation xml:lang="ru">Singh R., Nime F., Mittelman A. Malignant epithelian tumors of the anal canal. Cancer 1981;48(2):411–5.</mixed-citation></citation-alternatives></ref><ref id="B6"><label>6.</label><citation-alternatives><mixed-citation xml:lang="en">6. Жданов Д.А. Общая анатомия и физиология лимфатической системы. Л.: Медгиз, 1952. С. 336.</mixed-citation><mixed-citation xml:lang="ru">Жданов Д.А. Общая анатомия и физиология лимфатической системы. Л.: Медгиз, 1952. С. 336.</mixed-citation></citation-alternatives></ref><ref id="B7"><label>7.</label><citation-alternatives><mixed-citation xml:lang="en">7. NCCN Clinical practice guidelines in oncology: anal carcinoma. V. 1. 2013. URL: http://www.nccn.org (дата обращения 01.02.2013).</mixed-citation><mixed-citation xml:lang="ru">NCCN Clinical practice guidelines in oncology: anal carcinoma. V. 1. 2013. URL: http://www.nccn.org (дата обращения 01.02.2013).</mixed-citation></citation-alternatives></ref><ref id="B8"><label>8.</label><citation-alternatives><mixed-citation xml:lang="en">8. Brown G., Dighe S., Taylor F. Clinical staging: CT and MRI. Current Clinical Oncology: Rectal Cancer. Springer, 2010. P. 21–35.</mixed-citation><mixed-citation xml:lang="ru">Brown G., Dighe S., Taylor F. Clinical staging: CT and MRI. Current Clinical Oncology: Rectal Cancer. Springer, 2010. P. 21–35.</mixed-citation></citation-alternatives></ref><ref id="B9"><label>9.</label><citation-alternatives><mixed-citation xml:lang="en">9. Leichman L., Nigro N., Vaitkevicius V.K. et al. Cancer of the anal canal: model for preoperative adjuvant combined modality therapy. Am J Med 1985;78:211–5.</mixed-citation><mixed-citation xml:lang="ru">Leichman L., Nigro N., Vaitkevicius V.K. et al. Cancer of the anal canal: model for preoperative adjuvant combined modality therapy. Am J Med 1985;78:211–5.</mixed-citation></citation-alternatives></ref><ref id="B10"><label>10.</label><citation-alternatives><mixed-citation xml:lang="en">10. Bartelink H., Roelofsen F., Eschwege F. et al. Concomitant radiotherapy and chemo-therapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: results of a phase III randomized trial of the European Organization for Research and Treatment of Cancer Radiotherapy and Gastrointestinal Cooperative Groups. J Clin Oncol 1997;15(5):2040–9.</mixed-citation><mixed-citation xml:lang="ru">Bartelink H., Roelofsen F., Eschwege F. et al. Concomitant radiotherapy and chemo-therapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: results of a phase III randomized trial of the European Organization for Research and Treatment of Cancer Radiotherapy and Gastrointestinal Cooperative Groups. J Clin Oncol 1997;15(5):2040–9.</mixed-citation></citation-alternatives></ref><ref id="B11"><label>11.</label><citation-alternatives><mixed-citation xml:lang="en">11. Nigro N.D., Seydel H.G., Considine B. Jr et al. Combined radiotherapy and chemo-therapy for squamous cell carcinoma of the anal canal. Cancer 1983;51:1826–9.</mixed-citation><mixed-citation xml:lang="ru">Nigro N.D., Seydel H.G., Considine B. Jr et al. Combined radiotherapy and chemo-therapy for squamous cell carcinoma of the anal canal. Cancer 1983;51:1826–9.</mixed-citation></citation-alternatives></ref><ref id="B12"><label>12.</label><citation-alternatives><mixed-citation xml:lang="en">12. Glynne-Jones R. Anal cancer: an examination of radiotherapy strategies. Int J Radiat Oncol Biol Phys 2011;79(5):1290–301.</mixed-citation><mixed-citation xml:lang="ru">Glynne-Jones R. Anal cancer: an examination of radiotherapy strategies. Int J Radiat Oncol Biol Phys 2011;79(5):1290–301.</mixed-citation></citation-alternatives></ref><ref id="B13"><label>13.</label><citation-alternatives><mixed-citation xml:lang="en">13. Ярмоненко С.П., Вайнсон А.А., Коноплянников А.Г. Клиническая радиобиология. М.: Медицина, 1992. 320 c.</mixed-citation><mixed-citation xml:lang="ru">Ярмоненко С.П., Вайнсон А.А., Коноплянников А.Г. Клиническая радиобиология. М.: Медицина, 1992. 320 c.</mixed-citation></citation-alternatives></ref><ref id="B14"><label>14.</label><citation-alternatives><mixed-citation xml:lang="en">14. Dubois J.B., Vieillot S., Moscardo C.L. et al. A Planning Study to Compare Plans Using Volumetric Arc Therapy or IMRT for the Treatment of Anal Canal Cancer. URL:http://www.abstractsonline.com (дата обращения 01.08.2013).</mixed-citation><mixed-citation xml:lang="ru">Dubois J.B., Vieillot S., Moscardo C.L. et al. A Planning Study to Compare Plans Using Volumetric Arc Therapy or IMRT for the Treatment of Anal Canal Cancer. URL:http://www.abstractsonline.com (дата обращения 01.08.2013).</mixed-citation></citation-alternatives></ref><ref id="B15"><label>15.</label><citation-alternatives><mixed-citation xml:lang="en">15. Bilimoria K.Y., Bentrem D.J., Rock C.E. et al. Outcomes and prognostic factors for squamous-cell carcinoma of the anal canal: analysis of patients from the National Cancer Data Base. Dis Colon Rectum 2009;52:624–31.</mixed-citation><mixed-citation xml:lang="ru">Bilimoria K.Y., Bentrem D.J., Rock C.E. et al. Outcomes and prognostic factors for squamous-cell carcinoma of the anal canal: analysis of patients from the National Cancer Data Base. Dis Colon Rectum 2009;52:624–31.</mixed-citation></citation-alternatives></ref><ref id="B16"><label>16.</label><citation-alternatives><mixed-citation xml:lang="en">16. Epidermoid anal cancer: results from the UKCCCR randomised trial of radiotherapy alone versus radiotherapy, 5-fluorouracil, and mitomycin. UKCCCR Anal Cancer Trial Working Party. UK Co-ordinating Committee on Cancer Research. Lancet 1996;348:1049–54.</mixed-citation><mixed-citation xml:lang="ru">Epidermoid anal cancer: results from the UKCCCR randomised trial of radiotherapy alone versus radiotherapy, 5-fluorouracil, and mitomycin. UKCCCR Anal Cancer Trial Working Party. UK Co-ordinating Committee on Cancer Research. Lancet 1996;348:1049–54.</mixed-citation></citation-alternatives></ref><ref id="B17"><label>17.</label><citation-alternatives><mixed-citation xml:lang="en">17. Ajani J.A., Winter K.A., Gunderson L.L. et al. Fluorouracil, mitomicin and radiotherapy vs fluorocil, cisplatin and radiotherapy for carcinoma of the anal canal: A randomized controlled trial. JAMA 2008;299(16):1914–21.</mixed-citation><mixed-citation xml:lang="ru">Ajani J.A., Winter K.A., Gunderson L.L. et al. Fluorouracil, mitomicin and radiotherapy vs fluorocil, cisplatin and radiotherapy for carcinoma of the anal canal: A randomized controlled trial. JAMA 2008;299(16):1914–21.</mixed-citation></citation-alternatives></ref><ref id="B18"><label>18.</label><citation-alternatives><mixed-citation xml:lang="en">18. Peiffert D., Gerard J.P., Ducreux M. et al. Induction chemotherapy (ICTA) and dose intercification of the radiation boost inlocally advanced anal canal carcinoma (LAACC): Definitive analysis of the Inter-group Accord 03 trial Fondation Francaise de Cancerologie Digestive. Radiother Oncol 2008;88(Suppl 2):S20 (abstract 65).</mixed-citation><mixed-citation xml:lang="ru">Peiffert D., Gerard J.P., Ducreux M. et al. Induction chemotherapy (ICTA) and dose intercification of the radiation boost inlocally advanced anal canal carcinoma (LAACC): Definitive analysis of the Inter-group Accord 03 trial Fondation Francaise de Cancerologie Digestive. Radiother Oncol 2008;88(Suppl 2):S20 (abstract 65).</mixed-citation></citation-alternatives></ref><ref id="B19"><label>19.</label><citation-alternatives><mixed-citation xml:lang="en">19. Marks L.B., Yorke E.D., Jackson A. et al.Use of normal tissue complication probability models in the clinic. Int J Radiat Oncol Biol Phys 2010;76(3 Suppl):S10–S9.</mixed-citation><mixed-citation xml:lang="ru">Marks L.B., Yorke E.D., Jackson A. et al.Use of normal tissue complication probability models in the clinic. Int J Radiat Oncol Biol Phys 2010;76(3 Suppl):S10–S9.</mixed-citation></citation-alternatives></ref><ref id="B20"><label>20.</label><citation-alternatives><mixed-citation xml:lang="en">20. Fleshner P.R., Chalasani S., Chang G.J. et al. Practice parameters for anal squamous neoplasms. Dis Colon Rectum 2008;51:2–9.</mixed-citation><mixed-citation xml:lang="ru">Fleshner P.R., Chalasani S., Chang G.J. et al. Practice parameters for anal squamous neoplasms. Dis Colon Rectum 2008;51:2–9.</mixed-citation></citation-alternatives></ref><ref id="B21"><label>21.</label><citation-alternatives><mixed-citation xml:lang="en">21. Saarilahti K., Arponen P., Vaalavirta L., Tenhunen M. The effect of intensity- modulated radiotherapy and high dose rate brachytherapy on acute and late radiotherapy-related adverse events following chemoradiotherapy of anal cancer. Radiother Oncol 2008;87:383–90.</mixed-citation><mixed-citation xml:lang="ru">Saarilahti K., Arponen P., Vaalavirta L., Tenhunen M. The effect of intensity- modulated radiotherapy and high dose rate brachytherapy on acute and late radiotherapy-related adverse events following chemoradiotherapy of anal cancer. Radiother Oncol 2008;87:383–90.</mixed-citation></citation-alternatives></ref><ref id="B22"><label>22.</label><citation-alternatives><mixed-citation xml:lang="en">22. Trautmann T.G., Zuger J.H. Positron emission tomography for pretreatment staging and posttreatment evaluation in cancer of the anal canal. Mol Imaging Biol 2005;7:309–13.</mixed-citation><mixed-citation xml:lang="ru">Trautmann T.G., Zuger J.H. Positron emission tomography for pretreatment staging and posttreatment evaluation in cancer of the anal canal. Mol Imaging Biol 2005;7:309–13.</mixed-citation></citation-alternatives></ref></ref-list></back></article>
